ROMAPHARM: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ROMAPHARM
Largest movements
- Cash +€203,657
up €203,657 (+144.5%), from €140,972 to €344,630
mainly Net result for the year (+€140,883) and Depreciation (+€108,567)
- Tangible fixed assets -€108,567
down €108,567 (-27.8%), from €390,720 to €282,153
of which Land and buildings: -€102,698
- Financial fixed assets -€72,846
down €72,846 (-4.7%), from €1.5m to €1.5m
- Receivables within one year +€68,217
up €68,217 (+17.3%), from €395,030 to €463,247
of which Trade receivables: +€48,422
- Reserves +€140,864
up €140,864 (+7.1%), from €2.0m to €2.1m
of which Distributable reserves: +€144,000
- Trade debts -€44,454
down €44,454 (-11.0%), from €403,273 to €358,819
- Gross operating margin -€70,123
down €70,123 (-10.4%), from €675,398 to €605,275
- Taxes -€14,408
down €14,408 (-21.6%), from €66,700 to €52,292
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,874,377 | €2,965,907 | +€91,530 | +3.2% |
| Fixed assets | 21/28 | €1,925,934 | €1,744,521 | -€181,413 | -9.4% |
| Tangible fixed assets | 22/27 | €390,720 | €282,153 | -€108,567 | -27.8% |
| Land and buildings | 22 | €378,155 | €275,457 | -€102,698 | -27.2% |
| Furniture and vehicles | 24 | €12,565 | €6,696 | -€5,869 | -46.7% |
| Financial fixed assets | 28 | €1,535,214 | €1,462,368 | -€72,846 | -4.7% |
| Current assets | 29/58 | €948,443 | €1,221,386 | +€272,942 | +28.8% |
| Stocks and contracts in progress | 3 | €402,779 | €393,063 | -€9,716 | -2.4% |
| Stocks | 30/36 | €402,779 | €393,063 | -€9,716 | -2.4% |
| Amounts receivable within one year | 40/41 | €395,030 | €463,247 | +€68,217 | +17.3% |
| Trade receivables | 40 | €381,111 | €429,533 | +€48,422 | +12.7% |
| Other amounts receivable | 41 | €13,919 | €33,714 | +€19,794 | +142.2% |
| Current investments | 50/53 | €5,412 | €16,415 | +€11,003 | +203.3% |
| Cash at bank and in hand | 54/58 | €140,972 | €344,630 | +€203,657 | +144.5% |
| Deferred charges and accrued income | 490/1 | €4,250 | €4,032 | -€218 | -5.1% |
| Total equity and liabilities | 10/49 | €2,874,377 | €2,965,907 | +€91,530 | +3.2% |
| Equity | 10/15 | €2,142,712 | €2,283,595 | +€140,883 | +6.6% |
| Contributions | 10/11 | €172,000 | €172,000 | = | 0.0% |
| Capital | 10 | €172,000 | €172,000 | = | 0.0% |
| Issued capital | 100 | €172,000 | €172,000 | = | 0.0% |
| Reserves | 13 | €1,970,298 | €2,111,161 | +€140,864 | +7.1% |
| Non-distributable reserves | 130/1 | €17,200 | €17,200 | = | 0.0% |
| Legal reserve | 130 | €17,200 | €17,200 | = | 0.0% |
| Tax-exempt reserves | 132 | €51,598 | €48,461 | -€3,136 | -6.1% |
| Distributable reserves | 133 | €1,901,500 | €2,045,500 | +€144,000 | +7.6% |
| Profit (loss) carried forward | 14 | €414 | €433 | +€19 | +4.5% |
| Provisions and deferred taxes | 16 | €1,615 | €0 | -€1,615 | -100.0% |
| Deferred taxes | 168 | €1,615 | €0 | -€1,615 | -100.0% |
| Amounts payable | 17/49 | €730,050 | €682,312 | -€47,738 | -6.5% |
| Amounts payable after more than one year | 17 | €259,424 | €269,514 | +€10,090 | +3.9% |
| Other amounts payable | 178/9 | €259,424 | €269,514 | +€10,090 | +3.9% |
| Amounts payable within one year | 42/48 | €470,627 | €412,450 | -€58,177 | -12.4% |
| Trade debts | 44 | €403,273 | €358,819 | -€44,454 | -11.0% |
| Suppliers | 440/4 | €403,273 | €358,819 | -€44,454 | -11.0% |
| Advances received on contracts in progress | 46 | €725 | €0 | -€725 | -100.0% |
| Taxes, remuneration and social security | 45 | €66,629 | €53,631 | -€12,998 | -19.5% |
| Taxes | 450/3 | €21,418 | €6,215 | -€15,202 | -71.0% |
| Remuneration and social security | 454/9 | €45,211 | €47,416 | +€2,204 | +4.9% |
| Other amounts payable | 47/48 | €0 | - | = | |
| Accrued charges and deferred income | 492/3 | €0 | €348 | +€348 | |
| Remuneration, social security and pensions | 62 | €285,974 | €283,821 | -€2,152 | -0.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €110,365 | €108,567 | -€1,798 | -1.6% |
| Other operating charges | 640/8 | €19,709 | €20,314 | +€605 | +3.1% |
| Gross operating margin | 9900 | €675,398 | €605,275 | -€70,123 | -10.4% |
| Operating profit (loss) | 9901 | €259,350 | €192,573 | -€66,777 | -25.7% |
| Financial income | 75/76B | €1,236 | €1,082 | -€154 | -12.5% |
| Recurring financial income | 75 | €1,236 | €1,082 | -€154 | -12.5% |
| Financial charges | 65/66B | €1,409 | €2,095 | +€687 | +48.7% |
| Recurring financial charges | 65 | €1,409 | €2,095 | +€687 | +48.7% |
| Profit (loss) for the period before taxes | 9903 | €259,177 | €191,559 | -€67,618 | -26.1% |
| Transfer from deferred taxes | 780 | €1,615 | €1,615 | +€0 | 0.0% |
| Income taxes | 67/77 | €66,700 | €52,292 | -€14,408 | -21.6% |
| Profit (loss) for the period | 9904 | €194,092 | €140,883 | -€53,210 | -27.4% |
| Transfer from tax-exempt reserves | 789 | €3,136 | €3,136 | +€0 | 0.0% |
| Profit (loss) for the period to be appropriated | 9905 | €197,228 | €144,019 | -€53,210 | -27.0% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.